Editorial Perspectives On Cell Line Development

  1. Genetically Engineering An IL-15 Superagonist 9/25/2020

    SOTIO’s genetically-engineered SO-C101 is showing promise as a monotherapy and combined with immunotherapies in pre-clinical tests and also recently in a phase I study. CBO Jens Hennecke, Ph.D. shared an update on the company’s Phase 1 progress and gave us a look behind the curtains at the work it took to get to the clinic.